Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer

Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer

NCT02284529•Sinphar Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Stage-Ⅱ Colorectal Cancer

Interventions

Orectalip

Locations

Taiwan

Locations (1)

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan

Key Dates

Start Date

October 1, 2012

Primary Completion Date

August 1, 2014

Completion Date

September 1, 2014

Last Updated

November 6, 2014

Sponsors

Lead Sponsor

Sinphar Pharmaceutical Co., Ltd

Collaborators

Taichung Veterans General Hospital

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 6, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions